PMID- 21898386
OWN - NLM
STAT- MEDLINE
DCOM- 20120126
LR  - 20220321
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 130
IP  - 3
DP  - 2012 Feb 1
TI  - mTOR as a therapeutic target in patients with gastric cancer.
PG  - 491-6
LID - 10.1002/ijc.26396 [doi]
AB  - The poor long-term outcomes associated with current chemotherapy treatment of 
      patients with advanced gastric cancer suggest a need for novel targeted agents 
      that may confer a better survival benefit. Evidence of mammalian target of 
      rapamycin (mTOR) activation has been demonstrated in patient-derived gastric 
      cancer cells and tumors. This review explores the relevance of the mTOR pathway 
      to gastric cancer pathogenesis and its potential as a therapeutic target in 
      patients with gastric cancer as well as presenting the first available clinical 
      data on mTOR inhibitors in this disease setting. Preclinical data suggest that 
      suppression of the mTOR pathway inhibited the proliferation of gastric cancer 
      cells and delayed tumor progression in in vitro and animal models. In the 
      clinical setting, the mTOR inhibitor everolimus has been active and well 
      tolerated in phase I/II studies of patients with chemotherapy-refractory 
      metastatic gastric cancer. Based on these promising results, everolimus currently 
      is being investigated as a monotherapy or in combination with chemotherapeutic 
      agents in ongoing phase II/III clinical studies.
CI  - Copyright (c) 2011 UICC.
FAU - Al-Batran, Salah-Eddin
AU  - Al-Batran SE
AD  - Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt, Germany. 
      albatran@aol.com
FAU - Ducreux, Michel
AU  - Ducreux M
FAU - Ohtsu, Atsushi
AU  - Ohtsu A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111005
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Everolimus
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Signal Transduction/drug effects
MH  - Sirolimus/analogs & derivatives/pharmacology/therapeutic use
MH  - Stomach Neoplasms/*drug therapy
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
EDAT- 2011/09/08 06:00
MHDA- 2012/01/27 06:00
CRDT- 2011/09/08 06:00
PHST- 2011/04/15 00:00 [received]
PHST- 2011/08/11 00:00 [accepted]
PHST- 2011/09/08 06:00 [entrez]
PHST- 2011/09/08 06:00 [pubmed]
PHST- 2012/01/27 06:00 [medline]
AID - 10.1002/ijc.26396 [doi]
PST - ppublish
SO  - Int J Cancer. 2012 Feb 1;130(3):491-6. doi: 10.1002/ijc.26396. Epub 2011 Oct 5.